This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Quality of Care  • Evidence-Based Medicine  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

How to Combine the Best Evidence on Benefits With the Best Data About Adverse Effects

Jan P. Vandenbroucke, MD, PhD; Bruce M. Psaty, MD, PhD

JAMA. 2008;300(20):2417-2419.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The central theme of the Institute of Medicine report on the US drug safety system was the need for a life cycle approach to drug evaluation: both the benefits and the risks need to be evaluated and integrated during the entire market life of a drug.¹ The Food and Drug Administration Amendments Act of 2007 also called on the agency to improve its methods of communicating risks and benefits to patients and physicians. The Institute of Medicine recommendation to "develop and continually improve a systematic approach to risk-benefit analysis for use throughout the [Food and Drug Administration] in the preapproval and postapproval settings" specifically acknowledges the need for and the challenges of the development of new methods of combining evidence about risks and benefits.¹

Information that combines the best evidence on benefits with the best data on risks is also . . . [Full Text of this Article]

Author Affiliations: Department of Epidemiology, Leiden University Medical Center, Leiden, the Netherlands (Dr Vandenbroucke); and the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington and Center for Health Studies, Group Health, Seattle (Dr Psaty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study
Gill et al.
Arch Intern Med 2009;169:867-873.
ABSTRACT | FULL TEXT  

The Role of Diabetes Educators in the Medical Home
O'Connor and Sperl-Hillen
Diabetes Spectr. 2009;22:124-126.
FULL TEXT  

Cochrane Public Health Review Group update: incorporating research generated outside of the health sector
Armstrong et al.
J Public Health (Oxf) 2009;31:187-189.
FULL TEXT